Anticoagulation Management for Paroxysmal Atrial Fibrillation

Introduction to Anticoagulation

The American College of Cardiology strongly recommends oral anticoagulation with either a direct oral anticoagulant (DOAC) at standard dosing or warfarin with a target INR of 2.0-3.0 for patients with paroxysmal atrial fibrillation and high stroke risk, with DOACs being the preferred option due to their superior safety profile and similar efficacy 1

Stroke risk in paroxysmal AF should be assessed using the CHA₂DS₂-VASc score, with the same criteria applied as for persistent or permanent AF 2
High-risk patients (CHA₂DS₂-VASc score ≥2) should receive oral anticoagulation regardless of whether their AF pattern is paroxysmal, persistent, or permanent 2
Bleeding risk assessment should be performed for all patients, focusing on modifiable risk factors such as uncontrolled blood pressure, labile INRs, alcohol excess, and concomitant use of NSAIDs or aspirin 1

Dabigatran: 150 mg twice daily (standard dose) with dose adjustment based on renal function; contraindicated in severe renal impairment 1
Rivaroxaban: 20 mg once daily with food (standard dose) with dose adjustment may be needed based on renal function 1
Edoxaban: 60 mg once daily (standard dose) with dose adjustment based on renal function 1

For patients with mechanical heart valves, warfarin is recommended with a target INR based on the type and location of the prosthesis (at least 2.5) 2
For patients with mitral stenosis, adjusted-dose warfarin is recommended rather than DOACs 1
For patients with end-stage renal disease or on dialysis, warfarin is preferred over DOACs 1
Renal function should be evaluated before initiating DOACs and reevaluated at least annually 2

DOACs have demonstrated a lower risk of intracranial hemorrhage compared to warfarin 1

For warfarin, INR should be monitored at least weekly during initiation and monthly when stable 3
For DOACs, renal function should be assessed before initiation and at least annually thereafter 2
The need for anticoagulation should be reevaluated at regular intervals 3

Using antiplatelet therapy alone (aspirin or clopidogrel) instead of oral anticoagulation in high-risk patients with paroxysmal AF 1
Discontinuing anticoagulation after cardioversion or ablation in patients with ongoing stroke risk factors 1
Overestimating bleeding risk leading to inappropriate withholding of anticoagulation 1
Inadequate INR control when using warfarin, which reduces both safety and effectiveness 1